Drug Profile
Metyrapone/oxazepam - Embera
Alternative Names: EMB 001C; EMB-001Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Louisiana State University
- Developer Embera NeuroTherapeutics
- Class Antidepressants; Antihormones; Anxiolytics; Behavioural disorder therapies; Benzene derivatives; Benzodiazepinones; Drug withdrawal therapies; Halogenated hydrocarbons; Ketones; Pyridines; Smoking cessation therapies
- Mechanism of Action GABA A receptor agonists; Glucocorticoid receptor antagonists; Steroid 11-beta-hydroxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cocaine-related disorders
Highest Development Phases
- Phase II/III Smoking withdrawal
- Phase II Cocaine-related disorders
- No development reported Eating disorders; Gambling; Post-traumatic stress disorders; Substance-related disorders
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Eating-disorders in USA (PO)
- 28 Feb 2024 No recent reports of development identified for preclinical development in Gambling in USA (PO)
- 28 Feb 2024 No recent reports of development identified for preclinical development in Post-traumatic-stress-disorders in USA (PO)